Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ProQR Therapeutics NV is a biotechnology business based in the US. ProQR Therapeutics shares (PRQR) are listed on the NASDAQ and all prices are listed in US Dollars. ProQR Therapeutics employs 181 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.79 |
|---|---|
| 52-week range | $0.53 - $9.09 |
| 50-day moving average | $0.71 |
| 200-day moving average | $4.18 |
| Wall St. target price | $2.39 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.96 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.789 from 2022-07-01
| 1 week (2022-06-28) | -0.50% |
|---|---|
| 1 month (2022-06-01) | N/A |
| 3 months (2022-04-01) | N/A |
| 6 months (2022-01-04) | -90.60% |
| 1 year (2021-07-02) | -87.88% |
|---|---|
| 2 years (2020-07-02) | -86.21% |
| 3 years (2019-07-05) | 9.23 |
| 5 years (2017-07-05) | 5 |
| Revenue TTM | $3.6 million |
|---|---|
| Gross profit TTM | $2.4 million |
| Return on assets TTM | -27.51% |
| Return on equity TTM | -85.02% |
| Profit margin | 0% |
| Book value | $1.41 |
| Market capitalisation | $55.5 million |
TTM: trailing 12 months
We're not expecting ProQR Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, ProQR Therapeutics's shares have ranged in value from as little as $0.53 up to $9.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProQR Therapeutics's is 0.9614. This would suggest that ProQR Therapeutics's shares are less volatile than average (for this exchange).
ProQR Therapeutics N. V. , a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc. , and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.